Overview

A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck

Status:
Active, not recruiting

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

Summary

The investigators will perform a randomized phase II study to investigate if the addition of cetuximab to MTX is beneficial for the patient. Because no data on this combination are available the investigators will start with a phase Ib study to investigate the feasibility of the schedule.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Radboud University

Collaborators:

Academisch Ziekenhuis Maastricht
Elisabeth-TweeSteden Ziekenhuis
Erasmus Medical Center
Leiden University Medical Center
Medical Center Haaglanden
Medical Centre Leeuwarden
Medisch Spectrum Twente
Merck Serono International SA

Treatments:

Cetuximab
Methotrexate